Establishment Labs (NASDAQ:ESTA) Stock Rating Lowered by Wall Street Zen

Establishment Labs (NASDAQ:ESTA - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Thursday.Get Establishment Labs alerts:A number of other equities research analysts also recently issued reports on the company. Stephens reissued an "overweight" rating and set a $52.00 price target on shares of Establishment Labs in a research report on Thursday, March 6th. BTIG Research assumed coverage on Establishment Labs in a research note on Friday, May 16th. They issued a "buy" rating and a $62.00 price objective on the stock. Finally, Needham & Company LLC raised shares of Establishment Labs from a "hold" rating to a "buy" rating and set a $48.00 target price for the company in a research report on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Establishment Labs has a consensus rating of "Moderate Buy" and an average target price of $55.33.Get Our Latest Research Report on ESTAEstablishment Labs Trading Up 0.4%Shares of ESTA traded up $0.13 during mid-day trading on Thursday, hitting $36.01. The company had a trading volume of 33,698 shares, compared to its average volume of 469,413. Establishment Labs has a 1-year low of $26.56 and a 1-year high of $58.00. The business's 50-day simple moving average is $34.42 and its 200-day simple moving average is $38.10. The stock has a market cap of $1.04 billion, a PE ratio of -13.91 and a beta of 0.73. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94. Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.13. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The company had revenue of $41.38 million for the quarter, compared to the consensus estimate of $41.15 million. During the same quarter last year, the firm posted ($0.58) earnings per share. Establishment Labs's revenue was up 11.3% on a year-over-year basis. Sell-side analysts forecast that Establishment Labs will post -2.41 earnings per share for the current year. Institutional Investors Weigh In On Establishment LabsLarge investors have recently modified their holdings of the stock. Raymond James Financial Inc. purchased a new stake in shares of Establishment Labs during the fourth quarter valued at approximately $5,494,000. KLP Kapitalforvaltning AS acquired a new stake in Establishment Labs during the 4th quarter valued at $161,000. Swiss National Bank increased its stake in Establishment Labs by 2.7% during the 4th quarter. Swiss National Bank now owns 38,500 shares of the company's stock worth $1,774,000 after buying an additional 1,000 shares during the period. Sei Investments Co. increased its stake in Establishment Labs by 22.3% during the 4th quarter. Sei Investments Co. now owns 42,471 shares of the company's stock worth $1,957,000 after buying an additional 7,731 shares during the period. Finally, Royce & Associates LP acquired a new position in Establishment Labs in the 4th quarter worth $4,862,000. Institutional investors and hedge funds own 72.91% of the company's stock. Establishment Labs Company Profile (Get Free Report)Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.Further ReadingFive stocks we like better than Establishment LabsWith Risk Tolerance, One Size Does Not Fit All3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any MarketHow to Invest in the FAANG StocksThese 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1Expert Stock Trading Psychology TipsBuy the Dip? 3 Oil Stocks Poised for a Big ComebackThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Establishment Labs Right Now?Before you consider Establishment Labs, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Establishment Labs wasn't on the list.While Establishment Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here